Impact of MELD score implementation on liver allocation: experience at a Brazilian center
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 3
Abstract
Introduction. Model for end-stage liver disease (MELD) is an accurate predictor of mortality in patients with cirrhosis, and has been used on liver allocation in Brazil since 2006. However, its impact on organ allocation, waiting list and post-transplant mortality is still poorly characterized. This study aimed to assess the impact of implementation of the MELD system on liver allocation and mortality after liver transplantation (LT) in Southern Brazil. Material and methods. Adult patients with chronic liver disease on the waiting list for primary deceased-donor LT were divided into two cohorts (pre- and post-MELD implementation) according to the date of waiting list placement. Disease severity, as assessed by MELD score at placement, was similar in both cohorts. Patients were followed for at least 18 months to assess the outcomes of interest (death/LT). Results. Higher MELD scores correlated with waiting list mortality, which increased 20% with each additional point (HR 1.2; 95%CI 1.14-2.26; p < 0.001). Waiting list mortality was 30.9% before and 21.7% after MELD implementation (nonsignificant). Transplant rate increased after MELD implementation (52 vs. 40%, p = 0.002). After excluding patients with hepatocellular carcinoma, mean MELD scores at LT were significantly higher in the MELD era (p < 0.01). There was no significant correlation between MELD scores at LT and post-LT survival. During 18-month follow-up, post-LT mortality rate was 25.4% before and 20% after MELD implementation (nonsignificant). Conclusion. MELD implementation was associated with a reduction in waiting list mortality. Although sicker patients received LT in the MELD era, post-transplant survival was similar in both periods.
Authors and Affiliations
Adriana da Silva Machado, Alfeu de Medeiros Fleck Jr, Cláudio Marroni, Maria Zanotelli, Guido Cantisani, Ajácio de Mello Brandão
Keywords
Related Articles
- EP ID EP78283
- DOI -
- Views 127
- Downloads 0
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2...
Primary hepatic amyloidosis: a mini literature review and five cases report
Primary hepatic amyloidosis (PHA) is characterized by abnormal deposition of monoclonal immunoglobulin light chains (AL) in the liver. This rare condition is frequently undiagnosed or misdiagnosed and can be associated w...
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C
What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system
Background and rationale for the study. There is currently no definition of post-transjugular intrahepatic portosystemic shunt(TIPS) liver failure (PTLF), which constitutes a barrier to standardization of TIPS results r...
Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosisin patients with nonalcoholic fatty liver disease (NAFLD)
Background & Aim: Imaging modalities have a role in the diagnosis of patients with nonalcoholic fatty liver disease. Aim of the present study was to evaluate the role of chemical shift magnetic resonance imag...